Breaking News Instant updates and real-time market news.

RTRX

Retrophin

$20.08

-1.31 (-6.12%)

, CARA

Cara Therapeutics

$11.97

0.27 (2.31%)

04:55
11/20/16
11/20
04:55
11/20/16
04:55

American Society of Nephrology to hold a conference

ASN Kidney Week 2016 is being held in Chicago on November 15-20.

RTRX

Retrophin

$20.08

-1.31 (-6.12%)

CARA

Cara Therapeutics

$11.97

0.27 (2.31%)

CCXI

ChemoCentryx

$7.98

0.04 (0.50%)

ANTH

Anthera

$1.83

-0.06 (-3.17%)

  • 29

    Nov

RTRX Retrophin
$20.08

-1.31 (-6.12%)

11/11/16
LEER
11/11/16
NO CHANGE
LEER
Outperform
Retrophin agreement for RE-024 bodes well for approval in 2019, says Leerink
Leerink analyst Joseph Schwartz says that the trial design for Retrophin's pending Phase 3 trial of RE-024 and the announced agreement with the FDA under the Special Protocol Assessment process for this trial bode well for potential approval in 2019. The analyst believes the company plans to initiate this trial by the end of 2016, with a drug that has shown "great promise" for the treatment of pantothenate kinase-associated neurodegeneration. He reiterates an Outperform rating on the shares.
09/08/16
BMOC
09/08/16
NO CHANGE
BMOC
Retrophin price target raised to $40 from $28 at BMO Capital
BMO Capital analyst Do Kim raised the price target on Retrophin after the company reported Phase II data for its Sparsentan drug that the analyst views positively. Kim now sees a 45% chance of success for the drug, up from 25% previously. The analyst keeps an Outperform rating on the shares.
09/07/16
LEER
09/07/16
NO CHANGE
LEER
Outperform
Retrophin price target raised to $32 from $27 at Leerink
Leerink analyst Joseph Schwartz said he is "very optimistic" that sparsentan will be approved after Retrophin announced top-line results for its Phase 2b DUET study. However, he thinks it is still unclear if the results reported today will be enough to support accelerated approval or if another clinical trial will be required. Schwartz raised his price target on Retrophin to $32 from $27 following the data release and keeps an Outperform rating on the shares.
09/07/16
ROTH
09/07/16
NO CHANGE
Target $151
ROTH
Buy
Ligand target raised to $151 after sparsentan data at Roth Capital
Roth Capital analyst Joseph Pantginis raised his price target for Ligand Pharmaceuticals (LGND) to $151 from $149 after the company's partner Retrophin (RTRX) announced positive data from the sparsentan Phase II study in focal segmental glomerulosclerosis patients. The analyst believes the data support a potential accelerated path forward and he reminds investors that FSGS has no approved therapies. Pantginis calls the data an important win for Ligand and Retrophin. He keeps a Buy rating on Ligand. The stock is up 7% to $115.21 in early trading.
CARA Cara Therapeutics
$11.97

0.27 (2.31%)

12/31/15
PIPR
12/31/15
NO CHANGE
Target $34
PIPR
Overweight
Cara Therapeutics called a top 2016 pick at Piper Jaffray
Piper Jaffray analyst Charles Duncan highlights Cara Therapeutics (CARA) as his top pick going into 2016. The analyst likens the company's position to Neurocrine's (NBIX) last year, which he points out gained 150% at the end of 2014 to present. Cara has "notable value creation" potential from two Phase III read-outs of candidates with a "well-vetted mechanism of action in large-market indications," Duncan tells investors in a New Year's Eve research note. The analyst expects Cara's peak sales to reach four times its current market capitalization. He recommends buying the stock ahead of the Phase III readouts and keeps an Overweight rating on the stock with a $34 price target. Duncan expects the company to begin a pivotal trial of IV'845 in uremic pruritus in early 2016, with data being announced likely in Q4. Cara closed yesterday down 33c to $15.79 with a market cap of just below $440M.
02/26/16
CANT
02/26/16
NO CHANGE
CANT
Delay caused by Cara Therapeutics hold will be short, says Cantor
After Cara announced a clinical hold on the Phase III trial of its IV CR845 drug for post-surgical pain, the firm thinks the hold was unnecessary and does not expect it to delay the drug's advancement for more than three months. Cantor keeps a $28 price target and Buy rating on the shares.
10/13/16
HCWC
10/13/16
INITIATION
Target $20
HCWC
Buy
Cara Therapeutics initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Corey Davis started Cara Therapeutics with a Buy rating and $20 price target. The company's CR845 presents an opportunity treat peripheral pain without addiction potential, the analyst contends.
CCXI ChemoCentryx
$7.98

0.04 (0.50%)

ANTH Anthera
$1.83

-0.06 (-3.17%)

11/11/16
SBSH
11/11/16
NO CHANGE
Target $6
SBSH
Buy
Anthera price target lowered to $6 from $10 at Citi
Citi analyst Yigal Nochomovitz lowered his price target for Anthera Pharmaceuticals to $6 after the company announced that its Phase III trial failed to meet the primary endpoint in systemic lupus erythematosus. The result is not a "huge surprise" as the program always carried high risk, Nochomovitz tells investors in a research note. The analyst keeps a Buy rating on the shares, citing significantly higher conviction for Sollpura. He recommends buying on yesterday's weakness.
07/08/16
07/08/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Yelp (YELP) initiated with a Neutral at Wedbush. 2. PayPal (PYPL) initiated with an Overweight at Stephens. 3. GrubHub (GRUB) initiated with an Outperform at Wedbush. 4. Anthera (ANTH) initiated with a Buy at H.C. Wainwright. 5. 58.com (WUBA) initiated with an Outperform at Macquarie. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
07/08/16
HCWC
07/08/16
INITIATION
Target $10
HCWC
Buy
Anthera initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Andrew Fein initiated Anthera with a Buy and $10 price target saying shares are attractive ahead of the Sollpura topline data expected by year-end.
03/29/16
SBSH
03/29/16
NO CHANGE
SBSH
Citi lays out potential targets for next biotech M&A wave
Citi analyst Yigal Nochomovitz believes the setup for the next acquisition cycle in the biotech space is here, but that biotech management's desire to do deals is the missing catalyst. He thinks another one-to-three quarters is needed before "reset valuations are better absorbed as the new reality." Large cap pharma and biotech companies are cash rich and have signaled repeatedly over last year that they are looking for new assets, Nochomovitz tells investors in a research note. He sees a "greater probability" of a takeover over the next 12-18 months for Ardelyx (ARDX), Medivation (MDVN), Ophthotech (OPHT), Puma Biotechnology (PBYI), Portola Pharmaceuticals (PTLA), Ultragenyx (RARE), Relypsa (RLYP) and Versartis (VSAR). He sees a "moderate probability" of a takeover for Anthera (ANTH), Loxo Oncology (LOXO), MacroGenics (MGNX) and Mirati Therapeutics (MRTX). Nochomovitz also sees a "lower probability" of a buyout for Atara Biotherapeutics (ATRA), Chimerix (CMRX), Keryx (KERX) and Mirna Therapeutics (MIRN).

TODAY'S FREE FLY STORIES

REED

Reed's

13:06
04/24/17
04/24
13:06
04/24/17
13:06
Earnings
Reed's reports 2016 EPS (36c) vs. (30c) last year »

Reports 2016 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

KO

Coca-Cola

$43.40

0.33 (0.77%)

13:05
04/24/17
04/24
13:05
04/24/17
13:05
Technical Analysis
Coca-Cola technical comments ahead of results »

There is a bullish…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 26

    Apr

  • 09

    May

REED

Reed's

13:05
04/24/17
04/24
13:05
04/24/17
13:05
Earnings
Reed's sees Q1 revenue $8.3M vs. $10M last year »

Reed's said it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

13:05
04/24/17
04/24
13:05
04/24/17
13:05
General news
FX Action: USD-CAD »

FX Action: USD-CAD topped…

REED

Reed's

13:03
04/24/17
04/24
13:03
04/24/17
13:03
Hot Stocks
Reed's founder and CEO resigns, becomes Chief Innovation Officer »

Reed's announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

REED

Reed's

13:02
04/24/17
04/24
13:02
04/24/17
13:02
Syndicate
Reed's closes $3.4M private placement »

Reed's announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

BDX

Becton Dickinson

$178.36

-6.93 (-3.74%)

13:00
04/24/17
04/24
13:00
04/24/17
13:00
Upgrade
Becton Dickinson rating change  »

Becton Dickinson upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 04

    May

  • 06

    Jun

JNJ

Johnson & Johnson

$122.72

0.96 (0.79%)

, NVS

Novartis

$74.36

0.955 (1.30%)

12:57
04/24/17
04/24
12:57
04/24/17
12:57
Periodicals
J&J, Novartis, Takeda in talks over Hypermarcas takeover, Reuters says »

Johnson & Johnson…

JNJ

Johnson & Johnson

$122.72

0.96 (0.79%)

NVS

Novartis

$74.36

0.955 (1.30%)

TKPYY

Takeda Pharmaceutical Co. Ltd.

$24.29

0.215 (0.89%)

HYPMY

Hypermarcas

$9.66

0.44 (4.77%)

BBD

Banco Bradesco

$10.17

0.33 (3.35%)

CS

Credit Suisse

$15.16

0.705 (4.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 06

    Jun

  • 26

    Jun

REED

Reed's

12:56
04/24/17
04/24
12:56
04/24/17
12:56
Hot Stocks
Breaking Hot Stocks news story on Reed's »

Reed's trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

AMZN

Amazon.com

$898.53

-3.53 (-0.39%)

, W

Wayfair

$46.66

0.7 (1.52%)

12:55
04/24/17
04/24
12:55
04/24/17
12:55
Periodicals
Amazon hopes to launch furniture seller program, Furniture Today reports »

In a report highlighted…

AMZN

Amazon.com

$898.53

-3.53 (-0.39%)

W

Wayfair

$46.66

0.7 (1.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 27

    Apr

  • 09

    May

  • 16

    May

  • 17

    May

  • 23

    May

MMM

3M

$193.60

2.1 (1.10%)

12:55
04/24/17
04/24
12:55
04/24/17
12:55
Technical Analysis
3M technical notes before earnings news »

The stock has recently…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 09

    May

  • 31

    May

CAT

Caterpillar

$96.85

2.53 (2.68%)

12:52
04/24/17
04/24
12:52
04/24/17
12:52
Earnings
On The Fly: What to watch in Caterpillar earnings report »

Caterpillar (CAT) is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 09

    May

  • 14

    Jun

MU

Micron

$27.32

-0.64 (-2.29%)

12:51
04/24/17
04/24
12:51
04/24/17
12:51
Options
Bullish sentiment in Micron May 5th options ahead of a company event »

Bullish sentiment in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

  • 07

    Jun

AKRX

Akorn

$32.91

-0.09 (-0.27%)

, FSNUY

Fresenius SE

$19.67

-0.16 (-0.81%)

12:50
04/24/17
04/24
12:50
04/24/17
12:50
Periodicals
Akorn close to buyout deal at $33-$35/share, Reuters reports »

Akorn (AKRX) is near a…

AKRX

Akorn

$32.91

-0.09 (-0.27%)

FSNUY

Fresenius SE

$19.67

-0.16 (-0.81%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KSU

Kansas City Southern

$89.22

1.23 (1.40%)

12:49
04/24/17
04/24
12:49
04/24/17
12:49
Hot Stocks
Fitch: Mexican regulation could pressure Kansas City Southern »

Kansas City Southern…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    May

  • 09

    May

AKRX

Akorn

$32.91

-0.09 (-0.27%)

, FSNUY

Fresenius SE

$19.67

-0.16 (-0.81%)

12:47
04/24/17
04/24
12:47
04/24/17
12:47
Periodicals
Breaking Periodicals news story on Akorn, Fresenius SE »

Sources: Fresenius could…

AKRX

Akorn

$32.91

-0.09 (-0.27%)

FSNUY

Fresenius SE

$19.67

-0.16 (-0.81%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKRX

Akorn

$32.91

-0.09 (-0.27%)

, FSNUY

Fresenius SE

$19.67

-0.16 (-0.81%)

12:44
04/24/17
04/24
12:44
04/24/17
12:44
Periodicals
Breaking Periodicals news story on Akorn, Fresenius SE »

Fresenius nears deal to…

AKRX

Akorn

$32.91

-0.09 (-0.27%)

FSNUY

Fresenius SE

$19.67

-0.16 (-0.81%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMA

Comerica

$70.71

2 (2.91%)

12:41
04/24/17
04/24
12:41
04/24/17
12:41
Options
Notable call write in Comerica as shares rally »

Notable call write in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

CRHM

CRH Medical

$5.75

-1.6 (-21.77%)

12:40
04/24/17
04/24
12:40
04/24/17
12:40
Recommendations
CRH Medical analyst commentary  »

Cantor discusses recent…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

GOOG

Alphabet

$843.19

1.54 (0.18%)

, GOOGL

Alphabet Class A

$858.95

-1.13 (-0.13%)

12:36
04/24/17
04/24
12:36
04/24/17
12:36
Hot Stocks
Google adds TV to 'DoubleClick' ad buying platform »

Google announced in its…

GOOG

Alphabet

$843.19

1.54 (0.18%)

GOOGL

Alphabet Class A

$858.95

-1.13 (-0.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 02

    May

  • 22

    May

ORAN

Orange SA

$15.98

0.935 (6.22%)

, FB

Facebook

$143.68

-0.12 (-0.08%)

12:36
04/24/17
04/24
12:36
04/24/17
12:36
Hot Stocks
Orange partners with Facebook to launch startup accelerator »

Orange is working with…

ORAN

Orange SA

$15.98

0.935 (6.22%)

FB

Facebook

$143.68

-0.12 (-0.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

BIIB

Biogen

$272.94

0.48 (0.18%)

12:32
04/24/17
04/24
12:32
04/24/17
12:32
Technical Analysis
Biogen technical remarks ahead of earnings news »

The stock has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 25

    Apr

  • 31

    May

XOP

SPDR Oil Exploration and Production Fund

$35.41

0.3 (0.85%)

12:31
04/24/17
04/24
12:31
04/24/17
12:31
Options
Defensive option play in SPDR Oil Exploration and Production ETF »

Defensive option play in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALXN

Alexion

$116.82

-1.9 (-1.60%)

12:26
04/24/17
04/24
12:26
04/24/17
12:26
Options
Alexion call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 23

    Oct

MCK

McKesson

$136.22

0.3 (0.22%)

, TSRO

Tesaro

$136.01

-3 (-2.16%)

12:26
04/24/17
04/24
12:26
04/24/17
12:26
Hot Stocks
Biologics Inc says selected as specialty pharmacy provider for Tesaro's Zejula »

Biologics Inc, a McKesson…

MCK

McKesson

$136.22

0.3 (0.22%)

TSRO

Tesaro

$136.01

-3 (-2.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    May

  • 30

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.